138 related articles for article (PubMed ID: 12089489)
1. Utility of follow-up studies using meta-[123 I]iodobenzylguanidine scintigraphy for detecting recurrent neuroblastoma.
Okuyama C; Ushijima Y; Kubota T; Nakamura T; Kikkawa M; Nishimura T
Nucl Med Commun; 2002 Jul; 23(7):663-72. PubMed ID: 12089489
[TBL] [Abstract][Full Text] [Related]
2. Radioiodinated meta-iodobenzylguanidine in the diagnosis of childhood neuroblastoma.
Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Conte M; Villavecchia GP; Garaventa A; Lanino E; De Bernardi B; Scopinaro G
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):21-4. PubMed ID: 9002744
[TBL] [Abstract][Full Text] [Related]
3. [Value of 123I-MIBG scanning, neuron-specific enolase and serum ferritin in the diagnosis and follow-up of patients with neuroblastoma].
Hervás Benito I; Rivas Sánchez A; Bello Arques P; Cañete A; Fernández JM; Saura Quiles A; González Cabezas P; Ruiz Rodríguez JC; Castell V; Pérez Pastor JL; Monfort JA; Mateo Navarro A
Rev Esp Med Nucl; 2001 Aug; 20(5):369-76. PubMed ID: 11470071
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of iodine-123-MIBG scintigraphy for patients with neuroblastoma detected by a mass screening survey.
Hashimoto T; Koizumi K; Nishina T; Abe K
Ann Nucl Med; 2003 Dec; 17(8):633-40. PubMed ID: 14971604
[TBL] [Abstract][Full Text] [Related]
5. [Scintigraphy with radioiodinated meta-iodobenzylguanidine in the diagnosis of neuroblastoma].
Müller-Gärtner HW; Erttmann R; Helmke K
Nuklearmedizin; 1985 Dec; 24(5-6):222-6. PubMed ID: 3912731
[TBL] [Abstract][Full Text] [Related]
6. [123I-MIBG scintigraphy in patients with neuroblastoma].
Koizumi M; Sawada H; Goto M; Iijima A; Watari T; Kurosawa H; Kurumada H; Sugita K; Furukawa T
Kaku Igaku; 1994 May; 31(5):507-11. PubMed ID: 8028223
[TBL] [Abstract][Full Text] [Related]
7. [Follow up control of stage IV neuroblastoma: 123I-MIBG scintigraphy, bone scintigraphy and catecholamine metabolites].
Kohnert K; Lerch H; Thelen M; Jürgens H; Schober O
Nuklearmedizin; 1996 Dec; 35(6):220-4. PubMed ID: 8999421
[TBL] [Abstract][Full Text] [Related]
8. [Metaiodobenzylguanidine scintigraphy in the diagnosis and followup of neuroblastoma. Apropos of 16 cases].
Hammami H; Hassine L; Mhiri A; Sellem A; Oubich F; Gharssallah L; Barsaoui S; Ben Brahim H
Tunis Med; 2007 May; 85(5):413-6. PubMed ID: 17657930
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine.
Edeling CJ; Büchler Frederiksen P; Kamper J; Jeppesen P
Nuklearmedizin; 1986 Oct; 25(5):172-5. PubMed ID: 3797256
[TBL] [Abstract][Full Text] [Related]
10. Follow-up in neuroblastoma: comparison of metaiodobenzylguanidine and a chimeric anti-GD2 antibody for detection of tumor relapse and therapy response.
Reuland P; Geiger L; Thelen MH; Handgretinger R; Haase B; Müller-Schauenburg W; Niethammer D; Bares R
J Pediatr Hematol Oncol; 2001 Oct; 23(7):437-42. PubMed ID: 11878578
[TBL] [Abstract][Full Text] [Related]
11. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
Matthay KK; Edeline V; Lumbroso J; Tanguy ML; Asselain B; Zucker JM; Valteau-Couanet D; Hartmann O; Michon J
J Clin Oncol; 2003 Jul; 21(13):2486-91. PubMed ID: 12829667
[TBL] [Abstract][Full Text] [Related]
12. Catecholamines influence myocardial 123I MIBG uptake in neuroblastoma patients.
van der Palen RL; Bulten BF; Mavinkurve-Groothuis AM; Bellersen L; van Laarhoven HW; Kapusta L; de Geus-Oei LF
Nuklearmedizin; 2013 Dec; 52(6):228-34. PubMed ID: 24045423
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
Schmidt M; Simon T; Hero B; Schicha H; Berthold F
Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of clinical utility of 123I-MIBG scintigraphy in localization of tumors of sympathetic and adrenomedullary origin--a report of multicenter phase III clinical trials].
Ishii K; Kubo A; Kusakabe K; Murata H; Masaki H; Horiike S; Hayashi A; Hara Y
Kaku Igaku; 2000 Jan; 37(1):43-59. PubMed ID: 10714067
[TBL] [Abstract][Full Text] [Related]
15. [Scintigraphic diagnosis of neuroblastoma using meta-iodobenzylguanidine].
Kimmig B; Brandeis WE; Eisenhut M; Ludwig R; Adolph J
Klin Padiatr; 1986; 198(3):224-9. PubMed ID: 3723986
[TBL] [Abstract][Full Text] [Related]
16. [123I-metaiodobenzylguanidine (MIBG) scintigraphy for the staging of neuroblastoma].
Okuyama C; Ushijima Y; Sugihara H; Okitsu S; Maeda T
Kaku Igaku; 1998 Nov; 35(9):835-42. PubMed ID: 9916399
[TBL] [Abstract][Full Text] [Related]
17. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
18. The impact of 123I-meta-iodobenzylguanidine scintigraphy on diagnostics and follow-up of neuroblastoma.
Abrahamsen J; Lyck B; Helgestad J; Frederiksen PB
Acta Oncol; 1995; 34(4):505-10. PubMed ID: 7605659
[TBL] [Abstract][Full Text] [Related]
19. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.
Perel Y; Conway J; Kletzel M; Goldman J; Weiss S; Feyler A; Cohn SL
J Pediatr Hematol Oncol; 1999; 21(1):13-8. PubMed ID: 10029806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
